Notice NOT-EB-18-025 from the NIH Guide for Grants and Contracts

Notice NOT-EB-18-026 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-002 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-DE-18-024 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-002 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-FD-19-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development through the characterization of the natural history of rare diseases/conditions with unmet needs. Through the support of efficient and innovative natural history studies, FDA expects to address critical knowledge gaps, to remove major barrier(s) to progress in the field, to exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and to inform current or future product development including the design of clinical trial(s) and to ultimately inform the development of medical products that meet patient needs.

Funding Opportunity RFA-AA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research

Funding Opportunity RFA-DK-18-018 from the NIH Guide for Grants and Contracts. This FOA invites applications for Clinical Centers to carefully characterize the normal course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. Clinical Centers will recruit and study pregnant women starting in the first trimester and continuing at least through delivery. A separate FOA (RFA-DK-18-019) will solicit a Biostatistics Research Center. Each Clinical Center applicant will propose a study design and provide detailed information about recruitment capacity. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

Funding Opportunity RFA-DK-18-019 from the NIH Guide for Grants and Contracts. This FOA invites applications for a Biostatistics Research Center to participate in a clinical consortium to carefully characterize the course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. A separate FOA (RFA-DK-18-018) invites Clinical Centers to recruit and study pregnant women starting in the first trimester, and continuing at least through delivery. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.

Funding Opportunity RFA-AI-18-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop biomarkers/bioassays, techniques and/or devices for use in the civilian population that are rapid, reliable, inexpensive and easy-to-use. This FOA will support approaches addressing one or more of the following research gaps: 1. Distinguish between the worried well and the exposed population, 2. Determine the radiation dose in the affected group, 3. Predict the acute and delayed radiation injuries to major organs/physiological systems by discovering biomarkers that can be used for triage and treatment decisions in the event of a large scale radiological incident.

Notice NOT-MH-18-057 from the NIH Guide for Grants and Contracts

Notice NOT-LM-19-001 from the NIH Guide for Grants and Contracts

Notice NOT-MD-18-018 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-052 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-001 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-18-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.

Funding Opportunity RFA-DK-18-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D), beta cell specific autoimmunity, or rare forms of islet dysfunction that may inform understanding of the pathogenesis of T1D , as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues and expand the existing PANC DB open-access resource database. HPAP is a component of HIRN, created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.